SCHEMBL1760923

SCHEMBL1760923

CCc1coc(C=O)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23784751 0.83 ALDH1A1 (0.32)
SCHEMBL28473089 0.82 ALDH1A1 (0.31)
SCHEMBL934450 0.78
SCHEMBL30579046 0.78 DAO (0.36)
SCHEMBL5831670 0.75 XDH (0.34)
SCHEMBL18231599 0.75 ALDH1A1 (0.30)
SCHEMBL17490660 0.72 HSP90AB1 (0.47)
SCHEMBL13206835 0.71 SIGMAR1 (0.42)
SCHEMBL12086915 0.71 ALDH1A1 (0.32)
SCHEMBL17410706 0.70 BACE1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022104-A1 AMINO COMPOUND AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2026-01-22 US disclosed
US-20260008901-A1 AMINO COMPOSITION AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2026-01-08 US disclosed
EP-4592281-A1 AMINO COMPOUND AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2025-07-30 EP disclosed
EP-4592280-A1 AMINO COMPOSITION AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2025-07-30 EP disclosed
EP-1697354-B1 ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS MERCK SHARP & DOHME (US) 2013-08-07 EP disclosed
EP-1697354-B1 ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS MERCK SHARP & DOHME (US) 2013-08-07 EP disclosed
EP-1485089-B1 COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES MERCK SHARP & DOHME (US) 2013-04-17 EP disclosed
EP-1485089-B1 COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES MERCK SHARP & DOHME (US) 2013-04-17 EP disclosed
EP-1539678-B1 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS MERCK SHARP & DOHME (US) 2012-09-05 EP disclosed
EP-1539678-B1 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS MERCK SHARP & DOHME (US) 2012-09-05 EP disclosed
EP-1539678-A1 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS SCHERING CORPORATION (US) 2005-06-15 EP disclosed
EP-1485089-A1 COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES SCHERING CORPORATION (US) 2004-12-15 EP disclosed
US-20040186142-A1 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands SCHERING CORPORATION PHARMACOPEIA, INC. 2004-09-23 US disclosed
US-20040147559-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION AND PHARMACOPEIA, INC. 2004-07-29 US disclosed
US-20040106794-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands SCHERING CORPORATION 2004-06-03 US disclosed
US-20040097547-A1 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands PHARMACOPEIA DRUG DISCOVERY 2004-05-20 US disclosed
WO-2004033440-A1 THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS SCHERING CORPORATION (US) 2004-04-22 WO disclosed
US-20040053953-A1 Treatment of chemokine mediated diseases SCHERING CORPORATION 2004-03-18 US disclosed
WO-2004011418-A1 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS SCHERING CORPORATION (US) 2004-02-05 WO disclosed
WO-2003080053-A1 COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES SCHERING CORPORATION (US) 2003-10-02 WO disclosed